October 12, 2017 Harvard’s Rudolph Tanzi, Ph.D., a Leader in Alzheimer’s Disease Genetics, Joins Cerevance’s Advisory Board
December 2, 2016 Cerevance Launched With New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases
